Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression

Hepatocellular carcinoma (HCC) has the third-highest incidence in cancers and has become one of the leading threats to cancer death. With the research on the etiological reasons for cirrhosis and HCC, early diagnosis has been placed great hope to form a favorable prognosis. Non-invasive medical imaging, including the associated contrast media (CM)-based enhancement scan, is taking charge of early diagnosis as mainstream. Meanwhile, it is notable that various CM with different advantages are playing an important role in the different imaging modalities, or even combined modalities. For both physicians and radiologists, it is necessary to know more about the proper imaging approach, along with the characteristic CM, for HCC diagnosis and treatment. Therefore, a summarized navigating map of CM commonly used in the clinic, along with ongoing work of agent research and potential seeded agents in the future, could be a needed practicable aid for HCC diagnosis and prognosis.

Automated summary

Hepatocellular carcinoma, ranking third in cancer incidence, poses a significant threat to cancer patients. Early diagnosis through research on cirrhosis and HCC offers hope for a favorable prognosis. Non-invasive medical imaging, particularly contrast media enhancement scan, has become the mainstream method for early diagnosis. Different contrast media with distinct advantages play important roles in various imaging modalities, necessitating knowledge of appropriate imaging approaches and characteristic contrast media for HCC diagnosis and treatment.